Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease

Annals of Neurology

Volumn 57, Issue 6, 2005, Pages 832-842

  Maruyama, Masahiro ^a   Higuchi, Makoto ^a,b   Takaki, Yoshie ^b   Matsuba, Yukio ^b   Tanji, Haruko ^a   Nemoto, Miyako ^a   Tomita, Naoki ^a   Matsui, Toshifumi ^a   Iwata, Nobuhisa ^b   Mizukami, Hiroaki ^c   Muramatsu, Shin Ichi ^c   Ozawa, Keiya ^c   Saido, Takaomi C ^b   Arai, Hiroyuki ^a   Sasaki, Hidetada ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN TAU PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TRANSPORT; SYNAPSE;

AGED; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; DOWN-REGULATION; EARLY DIAGNOSIS; EXCITATORY AMINO ACID AGONISTS; FEMALE; GENETIC VECTORS; HIPPOCAMPUS; HUMANS; KAINIC ACID; MALE; MICE; NEPRILYSIN; RATS;

EID: 20444426464     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20494     Document Type: Article

References (35)

1. Saido TC. Aβ metabolism: from Alzheimer research to brain aging control. In: Saido TC, ed. Aβ metabolism and Alzheimer's disease. Georgetown, TX: Landes Bioscience, 2003:1-16.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
3. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide (42) in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
4. Aral H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38:649-652.
5. Growdon JH. Biomarkers of Alzheimer disease. Arch Neurol 1999;56:281-283.
6. Maruyama M, Arai H, Sugita M, et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 2001;172:433-436.
7. 123I]iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry 2002;159:474-476.
8. Doody RS. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry 2003;64(suppl 9):11-17.
9. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2003;2:215-220.
10. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003;2:539-547.
11. 1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000;6:143-150.
12. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Aβ by neprilysin. Science 2001;292:1550-1552.
13. Fukami S, Watanabe K, Iwata N, et al. Aβ-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Aβ pathology. Neurosci Res 2002;43:39-56.
14. Iwata N, Mizukami H, Shirotani K, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 2004;24:991-998.
15. Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 2001;297:97-100.
16. Maruyama M, Matsui T, Tanji H, et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol 2004;61:716-720.
17. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
18. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
19. Hama E, Shirotani K, Iwata N, Saido TC. Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons. J Biol Chem 2004;279:30259-30264.
20. Edge AS. Deglycosylation of glycoproteins with trifluoromethanesulphonic acid: elucidation of molecular structure and function. Biochem J 2003;376:339-350.
21. DeMartos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002;81:229-236.
22. Saido TC, Yokota M, Nagao S, et al. Spatial resolution of fodrin proteolysis in postischemic brain. J Biol Chem 1993;268: 25239-25243.
23. Saito T, Takaki Y, Iwata N, et al. Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. Sci Aging Knowledge Environ 2003;2003:PE1.
24. Saido TC, Nakahara H. Proteolytic degradation of Aβ by neprilysin and other peptidases. In: Saido TC, ed. Aβ metabolism and Alzheimer's disease. Georgetown, TX: Landes Bioscience, 2003:61-80.
25. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-791.
26. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150-156.
27. Jensen M, Schroder J, Blomberg M, et al. Cerebrospinal fluid A β42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 1999;45:504-511.
28. Chubinskaya S, Mikhail R, Deutsch A, Tindal MH. ADAM-10 protein is present in human articular cartilage primarily in the membrane-bound form and is upregulated in osteoarthritis and in response to IL-1alpha in bovine nasal cartilage. J Histochem Cytochem 2001;49:1165-1176.
29. Osenkowski P, Toth M, Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol 2004;200:2-10.
30. Hesse C, Rosengren L, Vanmechelen E, et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2000;2:199-206.
31. Franz G, Beer R, Kampfl A, et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2003;60:1457-146L
32. Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2002;2: 131-150.
33. Marr RA, Rockenstein E, Mukherjee A, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003;23:1992-1996.
34. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40:1087-1093.
35. 42, through modulation of proteolytic degradation. Nat Med 2005;11:434-439.